Inhibrx (INBX)
(Delayed Data from NSDQ)
$34.16 USD
+0.10 (0.29%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $34.11 -0.05 (-0.15%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
INBX 34.16 +0.10(0.29%)
Will INBX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for INBX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INBX
Inhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates
BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates
INBX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pharma Stock Roundup: JNJ Reports Q4 Earnings, SNY Inks M&A Deal With INBX
Biotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & More
Inhibrx, Inc. (INBX) Soars 8.9%: Is Further Upside Left in the Stock?
Other News for INBX
As more rare disease therapies launch, their prices are rising
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Crinetics Pharmaceuticals (CRNX) and Inhibrx (INBX)
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Inhibrx reports Q4 EPS ($1.73), consensus ($1.04)
Inhibrx just downgraded at Jefferies, here's why